Prognostic Factors in Advanced Gastric Cancer Patients With Suprapancreatic Lymph Node MetastasisHidefumi Shiroshita1*, Norio Shiraishi2, Toru Kusano1, Tsuyoshi Etoh1, Seigo Kitano3 and Masafumi Inomata1
- Corresponding Author:
- Hidefumi Shiroshita
MD, Gastroenterological and Pediatric Surgery
Oita University, Faculty of Medicine, Oita 879-5593, Japan
Tel: (81) 97-586-5843
Fax: (81) 97-549-1778
E-mail: [email protected]
Received Date: December 02, 2015; Accepted Date: Decenber 28, 2015; Published Date: January 06, 2016
Citation: Shiroshita H, Shiraishi N, Kusano T, Etoh T, Kitano S, et al. (2016) Prognostic Factors in Advanced Gastric Cancer Patients With Suprapancreatic Lymph Node Metastasis. J Gastrointest Cancer Stromal Tumor 1:102. doi:10.4172/2572-4126.1000102
Copyright: © 2016 Shiroshita H, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Background: There are few comprehensive studies on the prognosis of patients with suprapancreatic lymph node (LN) metastasis. In the present study, we evaluated prognostic factors in gastric cancer patients with suprapancreatic LN metastasis.
Methods: Between June 1982 and February 2004, 62 patients with suprapancreatic LN metastasis underwent radical gastrectomy and LN dissection at Oita University. Clinicopathologic factors of advanced gastric cancer with metastatic suprapancreatic LN were examined by univariate and multivariate analysis to identify prognostic factors.
Results: Five-year survival was associated with growth type (localized vs. infiltrative; P<0.01), depth of invasion (Muscularis propria or subserosa vs. exposed beyond the serosa or invasion to adjuvant organ; P<0.01), number of metastatic LNs (<7 vs. ≥ 7; P<0.01), and number of metastatic suprapancreatic LNs (1 vs. ≥ 2; P<0.01). By univariate analysis, localized growth type, an absence of serosal invasion, a metastatic LN count <7, and only 1 metastatic suprapancreatic LN were identified as good prognostic factors. By multivariate analysis, only 1 metastatic suprapancreatic LN was identified as independent prognostic factors. With analysis using the Kaplan- Meier method, there was a significant difference between these two factors.
Conclusions: Only one metastatic suprapancreatic LN was prognostic factors in advanced gastric cancer with suprapancreatic LN metastasis.